Voices
Scott Kopetz: FDA Grants Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line mCRC
Scott Kopetz/LinkedIn

Scott Kopetz: FDA Grants Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line mCRC

Scott Kopetz, Associate Vice President for Translational Integration at MD Anderson Cancer Center, shared a post on X:

“Delighted to share the full FDA approval for first-line CRC encorafenib + cetuximab with either FOLFOX or FOLFIRI. The impact from BREAKWATER: Median OS doubled: 30.3 vs 15.1 months, higher PFS, ORR

Test for BRAF V600E rapidly and treat in first-line!”

Read More

Scott Kopetz: FDA Grants Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line mCRC

Other articles featuring Scott Kopetz on OncoDaily.

cancer FDA mCRC MD Anderson Cancer Center Metastatic colorectal cancer OncoDaily Oncology Scott Kopetz